M. Teng

Immunology · 2014–2018

A researcher in the Science corpus: 7 papers; trusts 9 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Teng trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. Guido Kroemer
  3. Daniel S. Chen
  4. Janis Taube
  5. L. Galluzzi
  6. L. Zitvogel
  7. Robert Schreiber
  8. Bryan A. Irving
  9. M. Smyth
  10. Oliver Kepp

Papers from M. Teng's perspective

Ordered by how strongly the researchers M. Teng trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (Nature)
  3. Immunogenic cell death in cancer therapy. (Annual Review of Immunology)
  4. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  5. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 (Clinical Cancer Research)
  6. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  7. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  8. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development (Cell)
  9. Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma (Cell Reports)
  10. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)

Their papers